Cobimetinib CAS No:934660-93-2

Delivery term:The date of payment from buyers deliver within days
  • Price:

    Negotiable

  • minimum:

  • Total supply:

  • Delivery term:

    The date of payment from buyers deliver within days

  • seat:

    Zhejiang

  • Validity to:

    Long-term effective

  • Last update:

    2017-12-27 20:05

  • Browse the number:

    374

Send an inquiries
+
Hangzhou Shitai Biotech Co.,Ltd
Contactaixin:

Contactaixin:

shitaishengwu(Mr.)  

Email:

telephone:

phone:

Area:

Zhejiang

Address:

#2-1214 , West Business Center, Gongshu District, Hangzhou City, China

Website:

http://www.tacon-china.net/ http://www.disigncn.com/com/shitaishengwu/

+

PRODUCT NAME

Cobimetinib

CAS No.:

934660-93-2

Synonyms

[3,4-Difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl][3-hydroxy-3-(2S)-2-piperidinyl-1-azetidinyl]methanone

GDC 0973;XL 518;

Formula:

C21H21F3IN3O2

Molecular Weight:

531.31000

PSA:

64.60000

LogP:

4.12080

Structure
  

Description: 

Cobimetinib (trade name Cotellic) is a MEK inhibitor developed by Exelixis and Genentech. It is used in combination with vemurafenib, a BRAF inhibitor, to treat melanoma. In November 2015, the U.S. Food and Drug Administration approved cobimetinib for unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib (Zelboraf). Cobimetinib is not indicated for treatment of patients with wild-type BRAF melanoma.
Cobimetinib in combination with vemurafenib is reportedly priced at $17,600 per month, or about $211,000 per year. A competing dual therapy, using dabrafenib along with trametinib, is also approved by the FDA, and is reported to cost $15,300 monthly, or $183,600 per year.
We can provide this product with purity 99%.

http://www.tacon-china.net/